Anita Bowman will delve into the clinical applications of MSK-IMPACT and MSK-ACCESS at MSK, illustrating how these technologies meet the personalized needs of patients. Through real-world case studies, she will showcase how a matched tumor-normal approach has enhanced diagnosis and treatment planning. This methodology not only minimizes false positives but also identifies clonal hematopoiesis of indeterminate potential (CHIP) and resistance mechanisms, improving precision in treatment strategies.

Learning Objectives

1. Understand the evolution and unique features of MSK’s genomic profiling programs (MSK-IMPACT and MSK-ACCESS) and their role in advancing precision oncology.
2. Explore the critical benefits of matched tumor-normal sequencing in reducing biological false positives, enabling accurate somatic variant identification, and enhancing germline analysis.
3. Analyze real clinical cases demonstrating how MSK’s genomic technologies inform decision-making.